Why Is Genmab Stock Trading Lower On Monday?

Core Insights - Genmab A/S announced updated data from the Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S) in advanced endometrial cancer patients, showing a 50.0% confirmed objective response rate (ORR) at a median follow-up of one year [1][3][5] Study Results - The study involved 64 heavily pretreated patients with advanced or recurrent endometrial cancer, with 50% ORR in the 100 mg/m² cohort, including two complete responses (CRs) [5] - In the 120 mg/m² cohort, the confirmed ORR was 44.1%, with one CR observed [6] - Among responders in the 100 mg/m² cohort, 63.6% maintained their responses at the one-year follow-up [3] Ongoing Trials - Continued evaluation of Rina-S is ongoing in the Phase 2 RAINFOL-01 trial and the Phase 3 RAINFOL-03 trial, focusing on its efficacy and safety in advanced or recurrent endometrial cancer [4] Safety Profile - Common treatment emergent adverse events (TEAEs) included cytopenias and low-grade gastrointestinal events, with no signals of ocular toxicities, neuropathy, or interstitial lung disease reported [6] Market Reaction - Following the announcement, Genmab's stock price decreased by 6.57%, trading at $30.99 [7]